Abstract
Cytogenetics has provided new insights into the biology and pathogenesis of myelodysplastic syndromes. In patients with refractory anemia, it has provided proof of clonality and has helped differentiate chronic myelomonocytic leukemia from chronic myeloid leukemia. As a prognostic tool, cytogenetics has been predictive of duration of survival and leukemic transformation. However, its role as an independent prognostic factor compared with recent prognostic scoring systems remains to be determined. New techniques such as fluorescent in situ hybridization using chromosome-specific DNA probes may expand the usefulness of cytogenetics. The prognostic impact of cytogenetics may not be fully realized until more effective treatments become available.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 10-18 |
| Number of pages | 9 |
| Journal | Blood Reviews |
| Volume | 7 |
| Issue number | 1 |
| DOIs | |
| State | Published - 1993 |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Hematology
- Oncology
Cite this
Karyotypic analysis in primary myelodysplastic syndromes. / Noël, P.; Tefferi, Ayalew; Pierre, R. V.; Jenkins, Robert Brian; Dewald, G. W.
In: Blood Reviews, Vol. 7, No. 1, 1993, p. 10-18.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Karyotypic analysis in primary myelodysplastic syndromes
AU - Noël, P.
AU - Tefferi, Ayalew
AU - Pierre, R. V.
AU - Jenkins, Robert Brian
AU - Dewald, G. W.
PY - 1993
Y1 - 1993
N2 - Cytogenetics has provided new insights into the biology and pathogenesis of myelodysplastic syndromes. In patients with refractory anemia, it has provided proof of clonality and has helped differentiate chronic myelomonocytic leukemia from chronic myeloid leukemia. As a prognostic tool, cytogenetics has been predictive of duration of survival and leukemic transformation. However, its role as an independent prognostic factor compared with recent prognostic scoring systems remains to be determined. New techniques such as fluorescent in situ hybridization using chromosome-specific DNA probes may expand the usefulness of cytogenetics. The prognostic impact of cytogenetics may not be fully realized until more effective treatments become available.
AB - Cytogenetics has provided new insights into the biology and pathogenesis of myelodysplastic syndromes. In patients with refractory anemia, it has provided proof of clonality and has helped differentiate chronic myelomonocytic leukemia from chronic myeloid leukemia. As a prognostic tool, cytogenetics has been predictive of duration of survival and leukemic transformation. However, its role as an independent prognostic factor compared with recent prognostic scoring systems remains to be determined. New techniques such as fluorescent in situ hybridization using chromosome-specific DNA probes may expand the usefulness of cytogenetics. The prognostic impact of cytogenetics may not be fully realized until more effective treatments become available.
UR - http://www.scopus.com/inward/record.url?scp=0027511657&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027511657&partnerID=8YFLogxK
U2 - 10.1016/0268-960X(93)90019-Z
DO - 10.1016/0268-960X(93)90019-Z
M3 - Article
C2 - 8467227
AN - SCOPUS:0027511657
VL - 7
SP - 10
EP - 18
JO - Blood Reviews
JF - Blood Reviews
SN - 0268-960X
IS - 1
ER -